Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer

This publication has 21 references indexed in Scilit:

• Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
  New England Journal of Medicine, 2016
• Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
  British Journal of Cancer, 2016
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
  New England Journal of Medicine, 2015
• FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
  Clinical Cancer Research, 2015
• PARP inhibitors: A new era of targeted therapy
  Maturitas, 2015
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
  Cancer Research, 2012
• The mutational landscape of lethal castration-resistant prostate cancer
  Nature, 2012
• PALB2/FANCN: Recombining Cancer and Fanconi Anemia
  Cancer Research, 2010
• Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
  New England Journal of Medicine, 2009
• The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
  Oncogene, 2006